What does this research mean for the field?

A coaxial fiber membrane (NanoMesh) codelivering temozolomide and hypoxia-inducible factor inhibitors synergistically improves median and long-term survival in glioblastoma models. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This research aims to explore the effectiveness of a new drug delivery system for treating glioblastoma using a combination of drugs.

May 17, 2026Open Access

Codelivery Material System of Polymer Microfiber Structures for Synergistic Localized Therapy of Glioblastoma

Key Points

This research aims to explore the effectiveness of a new drug delivery system for treating glioblastoma using a combination of drugs.
Evaluated in vitro cytotoxicity of drug combinations on various glioma cell lines.
Conducted preliminary animal studies with a three-drug-loaded NanoMesh.
Monitored median survival and long-term survival rates of subjects using the NanoMesh.
Median survival improved by over 50 days in treated animals.
Long-term survival rate reached 40% for subjects surviving beyond 120 days.
Identified synergistic combinations of temozolomide with HIF inhibitors.

Abstract

Glioblastoma is a highly aggressive brain tumor whose treatment has improved little over the past decade. We report on the synergistic effect of the FDA-approved anti-GBM drug (temozolomide) and inhibitors (acriflavine, PT2385) of hypoxia-inducible factors (HIFs) embedded into coaxial fiber membranes (NanoMesh). In vitro cytotoxicity has been evaluated for various glioma cell lines, and synergistic drug combinations have been identified. Preliminary animal studies with the three-drug-loaded NanoMesh indicate a significant improvement of median survival of >50 days and long-term (>120 days) survival rate of 40%, indicating the potential of this material platform as a translatable local GBM therapy.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper